Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus
- PMID: 33004546
- DOI: 10.1136/gutjnl-2020-322368
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus
Abstract
Objective: A global consensus meeting was held to review current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of Helicobacter pylori for prevention of gastric cancer (GC).
Methods: 28 experts from 11 countries reviewed the evidence and modified the statements using the Delphi method, with consensus level predefined as ≥80% of agreement on each statement. The Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach was followed.
Results: Consensus was reached in 26 statements. At an individual level, eradication of H. pylori reduces the risk of GC in asymptomatic subjects and is recommended unless there are competing considerations. In cohorts of vulnerable subjects (eg, first-degree relatives of patients with GC), a screen-and-treat strategy is also beneficial. H. pylori eradication in patients with early GC after curative endoscopic resection reduces the risk of metachronous cancer and calls for a re-examination on the hypothesis of 'the point of no return'. At the general population level, the strategy of screen-and-treat for H. pylori infection is most cost-effective in young adults in regions with a high incidence of GC and is recommended preferably before the development of atrophic gastritis and intestinal metaplasia. However, such a strategy may still be effective in people aged over 50, and may be integrated or included into national healthcare priorities, such as colorectal cancer screening programmes, to optimise the resources. Reliable locally effective regimens based on the principles of antibiotic stewardship are recommended. Subjects at higher risk of GC, such as those with advanced gastric atrophy or intestinal metaplasia, should receive surveillance endoscopy after eradication of H. pylori.
Conclusion: Evidence supports the proposal that eradication therapy should be offered to all individuals infected with H. pylori. Vulnerable subjects should be tested, and treated if the test is positive. Mass screening and eradication of H. pylori should be considered in populations at higher risk of GC.
Keywords: cancer prevention; gastric cancer; helicobacter pylori; helicobacter pylori - treatment; screening.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: J-ML reports receiving lecture fees from Takeda Pharmaceuticals (Taiwan) and Abbott Laboratories. PM reports receiving advisory and lecture fees from Bayer, Mayoly Spindler and Nordmark. DYG is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel H. pylori therapies and has received research support for culture of Helicobacter pylori.
Similar articles
-
AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review.Gastroenterology. 2025 Feb;168(2):405-416.e1. doi: 10.1053/j.gastro.2024.11.001. Epub 2024 Dec 23. Gastroenterology. 2025. PMID: 39718517 Review.
-
Chemoprevention of gastric cancer development after Helicobacter pylori eradication therapy in an East Asian population: Meta-analysis.World J Gastroenterol. 2020 Apr 21;26(15):1820-1840. doi: 10.3748/wjg.v26.i15.1820. World J Gastroenterol. 2020. PMID: 32351296 Free PMC article.
-
Chemoprevention of gastric cancer by Helicobacter pylori eradication and its underlying mechanism.J Gastroenterol Hepatol. 2019 Aug;34(8):1287-1295. doi: 10.1111/jgh.14646. Epub 2019 Mar 27. J Gastroenterol Hepatol. 2019. PMID: 30828872 Review.
-
Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development.World J Gastroenterol. 2014 May 14;20(18):5461-73. doi: 10.3748/wjg.v20.i18.5461. World J Gastroenterol. 2014. PMID: 24833876 Free PMC article. Review.
-
Metachronous gastric cancer after successful Helicobacter pylori eradication.World J Gastroenterol. 2014 Sep 7;20(33):11552-9. doi: 10.3748/wjg.v20.i33.11552. World J Gastroenterol. 2014. PMID: 25206262 Free PMC article. Review.
Cited by
-
Efficacy and safety of low-dose tetracycline, amoxicillin quadruple therapy in Helicobacter pylori infection: A retrospective single center study.World J Gastroenterol. 2024 Oct 21;30(39):4295-4304. doi: 10.3748/wjg.v30.i39.4295. World J Gastroenterol. 2024. PMID: 39492823 Free PMC article.
-
Effects of Helicobacter pylori infection on intestinal microbiota, immunity and colorectal cancer risk.Front Cell Infect Microbiol. 2024 Jan 26;14:1339750. doi: 10.3389/fcimb.2024.1339750. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38343887 Free PMC article. Review.
-
Current and Future Perspectives in the Diagnosis and Management of Helicobacter pylori Infection.J Clin Med. 2022 Aug 30;11(17):5086. doi: 10.3390/jcm11175086. J Clin Med. 2022. PMID: 36079015 Free PMC article. Review.
-
A positive feedback loop of the TAZ/β-catenin axis promotes Helicobacter pylori-associated gastric carcinogenesis.Front Microbiol. 2022 Dec 23;13:1065462. doi: 10.3389/fmicb.2022.1065462. eCollection 2022. Front Microbiol. 2022. PMID: 36620008 Free PMC article.
-
Human microbiomes in cancer development and therapy.MedComm (2020). 2023 Feb 26;4(2):e221. doi: 10.1002/mco2.221. eCollection 2023 Apr. MedComm (2020). 2023. PMID: 36860568 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous